142 related articles for article (PubMed ID: 10792847)
21. Effect of erythromycin treatment on antibody responses in pertussis.
Granström G; Granström M
Scand J Infect Dis; 1994; 26(4):453-7. PubMed ID: 7984978
[TBL] [Abstract][Full Text] [Related]
22. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis.
McGuirk P; McCann C; Mills KH
J Exp Med; 2002 Jan; 195(2):221-31. PubMed ID: 11805149
[TBL] [Abstract][Full Text] [Related]
23. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
Sato H; Sato Y
Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis.
Strugnell R; Dougan G; Chatfield S; Charles I; Fairweather N; Tite J; Li JL; Beesley J; Roberts M
Infect Immun; 1992 Oct; 60(10):3994-4002. PubMed ID: 1398911
[TBL] [Abstract][Full Text] [Related]
25. fim3-24/ptxP-3 genotype is associated to whooping cough outbreak in Brazilian Midwest: The selection of Bordetella pertussis strains driven by vaccine immunization.
de Paula VG; de Sousa RS; da Silva RCMR; Alves EG; Caetano AR; Ianella P; de Campos TA
Infect Genet Evol; 2024 Jul; 121():105599. PubMed ID: 38679113
[TBL] [Abstract][Full Text] [Related]
26. Immunoelectron microscopy of antigens of Bordetella pertussis using monoclonal antibodies to agglutinogens 2 and 3, filamentous haemagglutinin, pertussis toxin, pertactin and adenylate cyclase toxin.
Blom J; Heron I; Hendley JO
APMIS; 1994 Sep; 102(9):681-9. PubMed ID: 7946271
[TBL] [Abstract][Full Text] [Related]
27. Comparison of biological activities of Bordetella pertussis mutants lacking the ability to produce filamentous hemagglutinin with similar activities of other smooth strains.
Watanabe M; Munoz JJ
Microbiol Immunol; 1982; 26(10):965-9. PubMed ID: 6298581
[No Abstract] [Full Text] [Related]
28. An antigen-conserving ELISA for detecting human antibodies to Bordetella pertussis filamentous hemagglutinin.
Vernon SK; Wiener FP; Urbano C; Levner MH
J Biol Stand; 1986 Apr; 14(2):157-61. PubMed ID: 2876000
[No Abstract] [Full Text] [Related]
29. Evaluation of pooled and individual components of Bordetella pertussis as antigens in an enzyme immunoassay for diagnosis of pertussis.
He Q; Mertsola J; Himanen JP; Ruuskanen O; Viljanen MK
Eur J Clin Microbiol Infect Dis; 1993 Sep; 12(9):690-5. PubMed ID: 8243485
[TBL] [Abstract][Full Text] [Related]
30. Western blot analysis of antibody responses of young infants to pertussis infection.
Guiso N; Grimprel E; Anjak I; Bégué P
Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):596-600. PubMed ID: 8223658
[TBL] [Abstract][Full Text] [Related]
31. Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis.
Pittman M
Rev Infect Dis; 1979; 1(3):401-12. PubMed ID: 233166
[TBL] [Abstract][Full Text] [Related]
32. Synergistic effect of Bordetella pertussis lymphocytosis-promoting factor on protective activities of isolated Bordetella antigens in mice.
Robinson A; Irons LI
Infect Immun; 1983 May; 40(2):523-8. PubMed ID: 6301999
[TBL] [Abstract][Full Text] [Related]
33. [Immune response to various antigenic preparations of Bordetella pertussis in whooping cough patients and convalescents studied by immunoenzyme analysis].
Tsvetkova NV; Borisenko IuV; Selezneva TS; Baeva EA
Zh Mikrobiol Epidemiol Immunobiol; 1986 Oct; (10):53-6. PubMed ID: 2879403
[TBL] [Abstract][Full Text] [Related]
34. Role of pertussigen (pertussis toxin) on the mouse protective activity of vaccines made from Bordetella species.
Munoz JJ; Peacock MG
Microbiol Immunol; 1989; 33(4):341-55. PubMed ID: 2549344
[TBL] [Abstract][Full Text] [Related]
35. Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains.
Borisova O; Kombarova SY; Zakharova NS; van Gent M; Aleshkin VA; Mazurova I; Mooi FR
Clin Vaccine Immunol; 2007 Mar; 14(3):234-8. PubMed ID: 17202309
[TBL] [Abstract][Full Text] [Related]
36. [Immunobiologic activity of Bordetella pertussis strains defective in various virulence factors].
Smirnov VD; Chuprinina RP; Siundiukova RA; Maksiutov RV
Zh Mikrobiol Epidemiol Immunobiol; 1989 Mar; (3):8-10. PubMed ID: 2545060
[TBL] [Abstract][Full Text] [Related]
37. Antigenic analysis of the saccharide moiety of the lipooligosaccharide of Bordetella pertussis.
Brodeur BR; Martin D; Hamel J; Shahin RD; Laferrière C
Springer Semin Immunopathol; 1993; 15(2-3):205-15. PubMed ID: 8256198
[No Abstract] [Full Text] [Related]
38. Long-lived respiratory immune response to filamentous hemagglutinin following Bordetella pertussis infection.
Amsbaugh DF; Li ZM; Shahin RD
Infect Immun; 1993 Apr; 61(4):1447-52. PubMed ID: 8454349
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities.
Halperin SA; Barreto L; Eastwood BJ; Law B; Roberts EA
Arch Pediatr Adolesc Med; 1994 Nov; 148(11):1220-4. PubMed ID: 7921131
[No Abstract] [Full Text] [Related]
40. Seroepidemiology of pertussis in the Japanese population.
Takayama N; Watanabe H; Fujita I; Minamitani M
Med Microbiol Immunol; 1989; 178(1):1-8. PubMed ID: 2535885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
